Romark Laboratories, LC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$29.4M
Doctors Paid
4,220
Transactions
23,078
2020 Total
$6.3M
Payment Breakdown by Category
Research$28.2M (96.1%)
Food & Beverage$329,837 (1.1%)
Consulting$138,146 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $28.2M | 331 | 96.1% |
| Current or prospective ownership or investment interest | $579,632 | 49 | 2.0% |
| Food and Beverage | $329,837 | 21,610 | 1.1% |
| Consulting Fee | $138,146 | 68 | 0.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $55,600 | 54 | 0.2% |
| Entertainment | $29,384 | 549 | 0.1% |
| Gift | $6,716 | 417 | 0.0% |
Payments by Type
Research
$28.2M
232 transactions
General
$1.1M
22,747 transactions
Ownership
$0
99 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection | $16.3M | 2 | 98 |
| A Phase III Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide and Nitazoxanide Plus Oseltamivir in the Treatment of Acute Uncomplicated Influenza | $7.9M | 1 | 74 |
| Phase 3, Randomized, Double-Blind, Placebo-Controlled, Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19 | $2.3M | 0 | 17 |
| A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection | $1.3M | 0 | 18 |
| A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities | $302,528 | 0 | 13 |
| Phase 3, A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection | $79,000 | 0 | 12 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2018 |
|---|---|---|---|---|
| Dr. Thomas Magee, Md, MD | Internal Medicine | Los Angeles, CA | $1.2M | $0 |
| Jose Alonso Alonso, Psychiatrist Md, PSYCHIATRIST MD | Psychiatry | San Juan, PR | $89,000 | $0 |
| Dr. Subramanya Shastri, Md, MD | Specialist | Williamsville, NY | $41,588 | $0 |
| Jaime Bravo Castro, M.d, M.D | Ophthalmology | San Juan, PR | $39,000 | $0 |
| Dr. Dennis Min, D.o, D.O | Gastroenterology | Middletown, OH | $36,307 | $0 |
| Dr. Chelikani Varma, Md, MD | Adolescent Medicine | Depew, NY | $36,116 | $0 |
| Dr. Juan Cancio Acevedo, Md, MD | Diagnostic Radiology | San Juan, PR | $35,000 | $0 |
| Dr. Juan Nevarez Marrero, M.d, M.D | Ophthalmology | Guaynabo, PR | $32,000 | $0 |
| Dr. Dhananjaya Kamisetti, M.d, M.D | Anesthesiology | Williamsville, NY | $29,380 | $0 |
| Dr. Antolin Alvarez Pont, M.d, M.D | Ophthalmology | Santurce, PR | $29,000 | $0 |
| Dr. John Powers, M.d, M.D | Infectious Disease | Olney, MD | $26,584 | $0 |
| Dr. Kenneth Liszewski, Dmd, DMD | Dentist | Sarasota, FL | $26,000 | $0 |
| Amzi Sherling, D.d.s, D.D.S | General Practice | Oxford, MS | $24,000 | $0 |
| Dr. Robert Stone, M.d, M.D | Orthopaedic Surgery | Evanston, IL | $24,000 | $0 |
| Dr. Richard Beverly, M.d, M.D | Emergency Medicine | Mobile, AL | $21,888 | $0 |
| Nallasivam Vivekanandan, M.d, M.D | Anesthesiology | Williamsville, NY | $20,280 | $0 |
| Jose Matos, M.d, M.D | Ophthalmology | San Juan, PR | $19,500 | $0 |
| Dr. Kenton Forte, M.d, M.D | Cardiovascular Disease | Buffalo, NY | $19,500 | $0 |
| Robert Benish, M.d, M.D | Hospitalist | Palm Bay, FL | $17,752 | $0 |
| Caterina Oneto Araya, M.d, M.D | Gastroenterology | New York, NY | $16,323 | $0 |
| Unknown Provider | — | — | $16,000 | $0 |
| Dr. Roberto Alfonso, Md, MD | Procedural Dermatology | San Juan, PR | $16,000 | $0 |
| Zamir Brelvi, M.d, M.D | Gastroenterology | Newark, NJ | $14,107 | $0 |
| Sharad Lakdawala, M.d, M.D | Psychiatry | Tampa, FL | $13,000 | $0 |
| Dr. Anusuya Sendos, Md, MD | Family Medicine | Houston, TX | $13,000 | $0 |
Ad
Top Products
- Alinia Tablets 500mg 30 count bottle $1.5M
- Alinia $290,892
Associated Products (4)
- Alinia Tablets 500mg 30 count bottle $1.5M
- Alinia $290,892
- ALINIA $68,818
- Alinia for Oral Suspension $20,000
Payment Categories
- Food & Beverage $329,837
- Consulting $138,146
- Research $28.2M
About Romark Laboratories, LC
Romark Laboratories, LC has made $29.4M in payments to 4,220 healthcare providers, recorded across 23,078 transactions in the CMS Open Payments database. In 2020, the company paid $6.3M. The top product by payment volume is Alinia Tablets 500mg 30 count bottle ($1.5M).
Payments were distributed across 87 medical specialties. The top specialty by payment amount is Internal Medicine ($1.2M to 586 doctors).
Payment categories include: Food & Beverage ($329,837), Consulting ($138,146), Research ($28.2M).
Romark Laboratories, LC is associated with 4 products in the CMS Open Payments database, including Alinia Tablets 500mg 30 count bottle, Alinia, and ALINIA.